The intelligent search engine for biomedical specialists

"GoPubMed is a sort of an intelligent Google for biomedical specialists," explains Dr Michael Alvers, CEO and Co-founder of Transinsight. "The search engine saves time and so accelerates research significantly."

Founded in November 2005, Transinsight is a software company focused on the life sciences that provides products and solutions for intelligent search technologies. Their main product, GoPubMed, was partly developed during the IST project, Biogrid, by Professor Michael Schroeder and his research team from the Biotechnology Centre at the Technical University of Dresden.

"Biomedical researchers have to be familiar with a huge number of publications," notes Schroeder, Transinsight's Chief Scientific Officer and Co-founder. "The PubMed database currently contains 15 million biomedical publications that have to be assessed by research groups."

"Researchers in the biotech and pharmaceutical industries spend an average of 12.4 hours a week searching for relevant information," adds Alvers.

GoPubMed can search literature repositories, websites, intranets and desktops. It indexes results and thus allows users to explore a large body of results in a structured manner.

In contrast to classical search engines, GoPubMed can answer questions using its background knowledge in molecular biology, medicine, drug development and food science. To illustrate this point, a search for 'aspirin inhibits' on a classical search engine returns a large number of unstructured results that do not answer the user's original question. On the other hand, a search with GoPubMed reveals that the most frequently mentioned pathway for 'aspirin inhibits' is the cyclooxygenase pathway.

Schroeder stresses, "GoPubMed] is intelligent and presents the search results in a way that is specifically linked to the interests of a particular research group."

Thanks to its groundbreaking and competitive product, the young company has already won its first corporate customer – Unilever in the UK. Explaining why Unilever decided to purchase the software, Dr Cecilia Eyre remarks "GoPubMed helps us to quickly screen the vast literature for hidden gems and to discover trends in science."

With exciting commercial prospects, the start-up company has also been quick to attract investment. This past January, it was announced that Transinsight had received €500,000 of seed funding from Germany's recently established High-Tech-Gründerfonds and a further undisclosed sum from a private investor in Hamburg.

Indeed, such are the high expectations for Transinsight, that the firm was very recently crowned as one of only three 'Lighthouse projects of the High-Tech-Gründerfonds' by Michael Glos, German Federal Minister for Economic Affairs and Technology.

Contact:
Dr Michael R. Alvers
CEO
Transinsight GmbH
Tatzberg 47-51
D-01307 Dresden
Germany
Tel: +49-351-46340059
Fax: +49-351-46340061
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Source: IST Results Portal

Most Popular Now

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...